Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Michael S. Brown net worth and biography

Michael Brown Biography and Net Worth

Director of Regeneron Pharmaceuticals

Michael S. Brown, M.D., has been a Director of the Company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London). Dr. Brown served as a member of the Board of Directors of Pfizer Inc.until April 2012.

What is Michael S. Brown's net worth?: The estimated net worth of Michael S. Brown is at least $969,956.70 as of June 14th, 2024. Dr. Brown owns 1,382 shares of Regeneron Pharmaceuticals stock worth more than $969,957 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Brown may own. Learn More about Michael S. Brown's net worth.
How do I contact Michael S. Brown?: The corporate mailing address for Dr. Brown and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Michael S. Brown's contact information.
Has Michael S. Brown been buying or selling shares of Regeneron Pharmaceuticals?: Michael S. Brown has not been actively trading shares of Regeneron Pharmaceuticals during the past quarter. Most recently, Michael S. Brown sold 1,535 shares of the business's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a transaction totalling $1,596,400.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company's stock, valued at $1,437,280. Learn More on Michael S. Brown's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Michael S. Brown Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2024	Sell	1,535	$1,040.00	$1,596,400.00	1,382
5/28/2024	Sell	1,172	$974.86	$1,142,535.92	1,382
12/27/2023	Sell	2,049	$898.00	$1,840,002.00	1,247
4/21/2023	Sell	3,070	$798.42	$2,451,149.40	1,247
1/27/2023	Sell	1	$747.00	$747.00	1,247
3/30/2022	Sell	408	$699.00	$285,192.00
9/13/2021	Sell	9,704	$648.16	$6,289,744.64	6,328
8/9/2021	Sell	1,687	$612.38	$1,033,085.06
6/25/2021	Sell	2,084	$549.00	$1,144,116.00	2,975
1/25/2021	Sell	2,480	$554.32	$1,374,713.60	3,371
7/1/2020	Sell	3,613	$607.62	$2,195,331.06	4,256
11/12/2019	Sell	4,500	$349.00	$1,570,500.00	4,823
9/27/2018	Sell	2,000	$392.26	$784,520.00	2,000
8/22/2018	Sell	1,500	$380.49	$570,735.00	1,500
10/5/2017	Sell	1,500	$475.00	$712,500.00
6/20/2017	Sell	3,000	$500.00	$1,500,000.00	3,000
5/12/2017	Sell	3,000	$450.00	$1,350,000.00	3,000
3/29/2017	Sell	1,000	$400.00	$400,000.00	1,000
12/10/2015	Sell	3,000	$546.45	$1,639,350.00
9/21/2015	Sell	3,000	$551.55	$1,654,650.00
5/15/2015	Sell	5,000	$495.00	$2,475,000.00
10/24/2014	Sell	5,000	$399.00	$1,995,000.00
8/15/2014	Sell	3,000	$349.20	$1,047,600.00
5/17/2013	Sell	15,000	$275.19	$4,127,850.00
11/14/2012	Sell	7,000	$147.03	$1,029,210.00

Michael S. Brown Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $701.85

$700.83

$717.61

50 Day Range

MA: $821.00

$701.85

$1,016.53

2 Week Range

Now: $701.85

$693.00

$1,211.20

Volume

1,889,979 shs

Average Volume

568,354 shs

Market Capitalization

$77.13 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.08